Nelly Shishkova

Generex Biotechnology Corp. (OTC:GNBT) Still Trades Massively

by Nelly Shishkova December 20, 2011


Generex.gifAs of October 31, liabilities of Generex were 50% higher than it total assets, stockholders' deficiency exceeded $7 million, and accumulated deficit remained over $347 million.

Having in mind that revenues of GNBT cannot cover any of the company's losses, Generex will keep existing under a going concern unless it finds additional financing to support its operations.

Type the characters that you see in the box (5 characters).